Abiopharma

🔍 Deen Diana G. (Executive)

Company: CATHAY GENERAL BANCORP (CATY)

Report Date: 2026-06-26

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-26 | Code: H
• Acquired 1,804 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-26 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,804.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F2, F2
• Acquired 1,700 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-26 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,700.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F2, F2
• Acquired 3,400 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-26 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,400.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F2, F2

Footnotes:

• F1: Each restricted stock unit represented a contingent right to receive one share of Common Stock upon vesting. The number of restricted stock units that are earned can be reduced by up to 100% of the target award or increased by up to 150% of the target award, depending upon the achievement of certain performance criteria.
• F2: These restricted stock units are scheduled to vest in a single installment on December 31, 2028, subject to continued employment, but may vest to some extent earlier in the event of death, disability, retirement after December 31, 2027 or a change in control, with the number of units earned being based on the achievement of certain performance criteria.